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1. Introduction
The microbe Mycobacterium tuberculosis (MTB) is an ancient cohabiter with humans, infecting al‐
most 3 billion people worldwide, 10% of them developing clinical disease. The 20th century
dream of eradicating the global scourge of tuberculosis (TB) evaporated with the failure of the
old BCG vaccine to protect the populations at greatest risk, low compliance at following the
complicated and lengthy treatment in countries with limited resources, which was followed by
the spread of multiple-drug resistant (MDR) strains. Actually the situation has worsened with a
peak of 9.4 millions of new clinical cases in 2009 and 1.7 million deaths/year [1,2,3].
However, it is intriguing to observe that the incidence and morbidity of the disease varies great‐
ly in different regions of the globe, being highest in Africa and Asia, as well as the response to
BCG vaccination [1,4]. That, in spite of the fact that there are no structurally variable strains of
MTB, therefore all have a similar virulence capacity. One important factor is the introduction of
the human immunodeficiency virus (HIV) into areas and populations already having a high TB
incidence [5], the resulting double infections having a disastrous effect. This is especially promi‐
nent in sub-Saharan Africa. But that factor alone can not explain the global epidemiological var‐
iability in the disease. Also, why only one in ten carriers of the microbe become clinically sick?
In order to address these questions, in the present chapter we will try to delve into the intri‐
cacies of the human immune response to MTB infection and to explore possible differences
in the genetic regulation of the host immune responses in various human populations.
2. The encounter of Mtb with the innate immune system
Most human infections with MTB occur through inhaled carrier droplets into the lower
airways. There the microbe encounters the alveolar macrophage (AMac) and submucosal
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dendritic cell (DC). The outcome of the ensuing battle will determine whether the infection
will remain locally limited within the engulfing cells of the innate immune system, or will
continue to spread, causing the individual to become a clinically active TB patient [1,6,7,8].
During the first contact, the AMac recognizes the microbe through pattern recognition
receptors (PRRs), which sense microbial biochemical components, such as outer coat manno‐
sylated lipoarabinomannan (ManLam), trehalose dimycolate and N-glycolymuramyl dipep‐
tide. These molecules act as pathogen-associated molecular patterns (PAMPs), which trigger
an intracellular signaling cascade in the AMac, which leads to a phagocytic activity, which, if
successful, will result into the complete engulfing of the microbe into cytosolic vesicles- the
phagolysozomes and secretion of pro-inflammatory cytokines, such as tumor-necrosis factor
alpha (TNFα). ManLam also binds directly to mannose receptors on macrophages and DCs.
The best studied PRRs are Toll-like receptors (TLRs) [6,9,10], of which 10 have been identified
in humans. TLR- 2 and TLR-4 recognize bacterial products [9,11], TLR-2 having a major role
in recognizing MTB in the lung. All contain an intracellular TIR domain, the activation of which
initiates a signaling cascade via adapter proteins such as MyD88, interferon-inducing TRIF
and TRIF-related adapter molecule TRAM, which results in the recruitment of interleu‐
kin-1(IL-1) receptor-associated kinase (IRAK) 4, which phosphorylates IRAK-1. The latter
binds to TNFα receptor-associated factor (TRAF) 6, leading to kinase-dependent IkBα
phosphorylation, the degradation of which leads to the activation of nuclear NF-kB, which is
the main nuclear activator of proinflammatory cytokines. Another intracellular PRR is
nucleotide-binding oligomerization domain 2 (NOD2), which binds bacterial cell-wall
muramyl-dipeptide, eliciting secretion of TNFα, IL-1β, IL-6 and bacteridal LL-37 [12,13]
Neutrophils also play a defensive role, not only as first-line non-specific phagocytes, but also
by secreting anti-bacterial proteins, mainly the cathelicidin LL-37 [1,14]. Neutrophils loaded
by phagocytized bacteria become apoptotic, thereby eliciting macrophage activation [15].
NK cells, which are large granular circulating lymphocytes, are attracted to the sites of bacterial
infections, where they specialize in recognizing and destroying infected host cells. During this
process they secrete interferon gamma (IFNγ), which activates macrophages, inducing them
to secrete the cytokines IL-12, IL-15 and IL-18, which activate CD8+T-cells, thus forming the
link to the adaptive immune system [7,16]
The complement is the humoral arm of the innate immune system. It has been shown that M.
bovis BCG may activate the three pathways of complement: the classical pathway by binding
to the C1q protein, the lectin pathway by binding to the bacterial cell surface mannose-binding
lectin (MBL) or L-ficolin and the alternate pathway through the deposition of C3b on the
bacterial surface. Mtb can activate the classical and alternate pathways by binding C3. This
enables complement to perform its major functions-microbial opsonization, microbial cell lysis
through the formation of the attack complex and leukocyte recruitment by eliciting chemokine
secretion [7,17].
Another recently discovered anti-microbial mechanism of phagocytic cells is the use of vital
transition metals, such as iron, zinc and copper, to poison intracellular microorganisms.
However, mycobacteria have developed a resistance mechanism to such intoxication [18,19].
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This contrasts with the function of the phagosomal metal transporter natural resistance-
associated membrane protein (NRAMP) 1 to deprive the microorganisms from essential
nutrients, such as iron and manganese [20]. Such duality existing in the same cell is of interest.
Virulent Mtbs have acquired the capability to dampen the activity of NF-Kb by some of their
antigens [6,7], such as ESAT-6 and ManLam. The latter also inhibits the secretion of IL-12, an
essential cytokine in the anti-MTB inflammatory response. ESAT-6 downregulates MyD88-
IRAK 4 interaction, thereby also interfering with TLR signaling to NFkB. A third antigen-
CFP-10 markedly reduces nitric oxide (NO) and reactive-oxygen species (ROS) production by
the macrophages, thereby inhibiting their non-specific killing ability. The microbe may also
regulate macrophage apoptosis to its advantage and to inhibit IFNγ- mediated macrophage
activation [7]. ESX is a recently discovered protein transport system through the outer
membrane of the microbe, which is essential for its survival. It has been demonstrated, in an
experimental model, that ESX-5 may modulate macrophage reactivity by dampening the
inflammasome activation [21]. These mechanisms enable the microbe to survive in the
macrophage phagosome in a balance which is precarious to the host. In addition Mtb may
escape the phagolysozome into the cytosol by damaging its membrane. Most recently it has
been described that the microbe may secrete toxins, such as the newly discovered MtpA
protein, through its outer membrane into the macrophage cytosol, which may cause the death
of the later by cell necrosis [22].
Vitamin D seems also to play an important role in the microbe-host pull-of-arms [23]. It may
modulate the inflammatory effect of some metalloproteinases (MMPs) in the lung [24] and
Vitamin D supplementation has hastened bacterial eradication in pulmonary tuberculosis in
a clinical trial [25].
Thus, the encounter between MTB and the various components of the innate immune system
induce a complicated and sophisticated series of host responses and counter responses by the
microbe. The later is one of the most ancient human infections, carried by our ancestors since
they fanned-out from Africa across the globe, therefore enabling it to adapt to the human
immune response (26-Cole S, Tuberculosis in time and space, Econference).
However, the next long-term phase of the encounter is played by the activation of the adaptive
immune system, as described in the next section.
3. The role of adaptive immunity in the outcome of the Infection
In the previous section the importance of the host innate immune response in the encounter
with MTB was described. However, it is generally accepted that the long-term outcome of the
primary infection is determined by the effective mobilization of the adaptive immune re‐
sponse. Active TB patients, as well as latently infected carriers, do not suffer from a general
innate or adaptive immune defect. On the contrary, ex-vivo studies of their immunocyte
function demonstrate increased lymphocyte proliferation and the secretion of numerous
cytokines [27]. Thus the disease, in people generally healthy, is a result of a very specific
immune failure in face of MTB, or other mycobacteria.
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It was thought that the CD4+T cell is the omnipotent determinant of the adaptive immune
response in TB. However, lately it became clear that more T-cell subsets, including CD8+ and
TH17 cells and even B cells participate in the process [1,7,28]. The induction phase seems to be
delayed relatively to the response to more common pathogens. It is initiated by signaling and
presentation of the microbial peptides by the macrophages and DCs to the CD4+ cells via MHC
class II molecules, while mycobacterial membranal lipids are presented through MHC-I
molecules of the CD-1 family [29]. The presentation of mycobacterial antigens occurs within
the draining lung lymph-nodes to which the macrophages have migrated, followed by the
activation of CD4+ and other T cells. These T cells use various receptors, such as TLRs, NOD-
like receptors and C-type lectins, for this purpose. The peptides considered as potentially
immunodominant are the already mentioned ESAT-6 and CFP10 and others, such as Rv2031c,
Rv2654c and Rv1038c. The T cell response to these antigens is not homogenous, various T cell
epitopes being engaged during the different phases of the infection [30]. Other Rv proteins are
binding to T cells mainly during the latent phase [31]. T cell activation, by the recognition of
these antigens in the initiating phase, results in the secretion of numerous cytokines, mostly
proinflammatory, such as IL-1β, IL-6, IL-21 and IL-12p40. The later activates CD4+TH1 cells,
but p40 is also a subunit of IL-23, which induces the TH17 cell lineage, which secretes IL-17,
IL-21 and IL-22. These cytokines are considered to be essential for anti-microbial protection
and IL-17 is thought to have a major role in granuloma formation [32], as well as TNFα, which
is also secreted by CD4+ cells and promotes intra-phagosomal killing of the bacteria in
macrophages. During an acute mycobacterial infection γδ T cells secrete much IL-17 [33],
which also promotes the secretion of IL-12, thus a self-enhancing inflammatory loop is being
formed. This is balanced by the secretion of TGFβ, the role of which is to dampen an over‐
reactive inflammatory response, partly so by inducing T-reg cells. The later may inhibit TH1
responses, thus potentially facilitating mycobacterial replication within macrophages [34]. A
high incidence of T reg Foxp3 cells has been found in extra-pulmonary TB [35].
The activated T cells undergo clonal expansion and migrate out of the lymph nodes into
the site of the infection in the lung, as effector T cells. This process is driven by chemo‐
kines, secreted by various inflammatory cells. Upon arrival to the battle ground they se‐
crete interferon gamma (IFNγ), which is a key cytokine in the ensuing confrontation, by
further  activating  the  microbicidal  machinery  of  the  macrophage  and  causing  it  to  se‐
crete IL-18, amongst other cytokines, which seems to be part of the protective TH1 type
response.  IFNγ  also  induces  the  production  of  toxic  NO  via  inducible  NO  synthase
(iNOS).  Casanova  et  al  [36,37,38]  have  described  in  detail  the  importance  of  the  IFNγ-
IL-12 cytokines loop, including their receptors, for TB immunity. Furthermore they have
described rare Mendelian genetic defects in this system, resulting in susceptibility to seri‐
ous mycobacterial and sometimes salmonellar infections.
CD8+ T cells also participate in the immune reaction, as they have been found in the me‐
diastinal lymph nodes, mixed with CD4+ cells and later at the infection site in the lungs.
Most  evidence  about  them  has  been  collected  in  mouse  and  primate  models  and  their
role in human infections has not been fully elucidated [7].It has been demonstrated in vi‐
tro that CD8+ cells recognize bacterial peptides and lipids through the MHC-I CD-1 mol‐
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ecules,  which induce a cytotoxic  response toward the bacteria  and to the phagocytes in
which they reside. They also secrete IFNγ and TNFα. Humans with latent TB develop a
high level of mycobacteria-specific CD8+ T cells [39].
From all the above it is clear that the dominant protective response in TB is Th1 type. However
in multiple-drug resistant (MDR) [40] and in young children [41] there is a skewing towards
a Th2 type response, with greater secretion of IL-4. This may explain why children tend to
develop pulmonary milliary and extrapulmonary disease. In addition it seems that the disease
in children tends to have a Mendelian heritability of specific defects, while in adults there is
no such background, rather some discrete polymorphisms may be found in different popula‐
tions, such as in the natural resistance-associated macrophage protein 1 (NRAMP1) [42].
For a long time it was generally accepted that B-cells and specific antibodies have no protective
role against TB. However monoclonal antibodies against some mycobacterial antigens have
shown a clear protective effect in mice [43]. It has been postulated that the unique phenomenon
of BCG protection against pediatric TB meningitis may be due in part to specific antibodies.
Presently the exact role of B-cells in human TB remains to be determined.
Similarly to the innate immune system, mycobacteria have also developed evasion tactics from
the adaptive immune system [44]. They may interfere with the antigen presentation process,
promote the secretion of IL-10 by T cells, thereby polarizing them toward a TH2 type response,
in which the essential IFNγ secretion is inhibited [7]. They may also attract more T-reg cells to
the infection site, thereby further dampening the protective inflammatory response. It was
demonstrated in a tuberculosis rabbit model, that mycobacteria may delay the macrophage
and T-cells activation process, thereby enabling them to form a permanent infection and
damaging pulmonary tissue [45]. More specifically, the bacteria possess a set of genes- rpf,
which code for the regulatory Rpf proteins, which are believed to be responsible for activating
bacteria from a dormant state in latency. In addition the bacteria have also a set of “anti-
dormancy genes”-DosR, which induce bacterial growth, when appropriate [46].
4. The tuberculous granuloma
The formation of granuloma is the host’s containment effort in response to an infection which
he can not eradicate. In most cases it results in a state of latency, with dormant, but viable,
bacteria residing in it [7, 45, 47]. Therefore the granuloma benefits also the bacteria, who may
emerge from dormancy, proliferate again and cause an active disease, if the host’s immune
system is weakened due to any reason. HIV coinfection, with its damage to T cells, has become
the most prominent example of this situation.
The granuloma contains a nucleus of necrotic lung tissue and intraphagosomal bacteria-
containing macrophages, surrounded by fibroblasts, DCs, neutrophils, B cells and various
subsets of T cells, all of those secreting cytokines, mainly IFNγ and TNFα, and chemokines
which ensure a continuous mobilization of granulocytes to the granuloma. TNFα activates
adhesion molecules on the immunocytes [48]. Thus the granuloma is a dynamic and continu‐
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ous battlefield balancing the bacteria against the immune system. Occasionally, as described
before, the bacteria may damage the phagosomal membrane and escape, inducing an apoptotic
or necrotic death of the macrophage. This enables the bacteria to proliferate with enhancement
of tissue damaging inflammation, which may result in cavity formation.
5. Shall we ever have an effective immunotherapy or anti-TB vaccine?
Application of highly effective vaccines across the globe is the only way to control and arrest
the spread of infectious diseases. So far BCG is the only available anti-TB vaccine. It is one of
the oldest vaccines and has remained unchanged for a long time. It does confer reasonable
protection to infants at risk and prevents pediatric TB meningitis. However it is ineffective for
protection of large adult populations and has failed to prevent the rise in new infections and
active disease patients and especially in MDR and extreme drug resistant (XDR) cases [49].
Therefore many efforts have been invested in trying many forms of various extracts of other
mycobacteria, such as M. vaccae, which may be considered as immunostimulants of TH1
responses or a kind of vaccines. Most have resulted in a transient enhancement of the anti-
tuberculous inflammatory response, sometimes with severe side-effects, but without long-
term clinical benefit [50]. How can this be explained?
The main reason is  that  decades of  research have not,  as  yet,  demonstrated a universal
clearly  immunodominant  and protective  T  cell  epitope  to  one of  the  bacterial  antigens-
mainly to cell-wall peptides, lipids or glycolipids. An exception may be the 85A and 85B
antigens,  which  may  be  suitable  candidates  for  a  widely  used  anti-tuberculous  vaccine
under various constructs [51]. They show enhancement of TH1-type responses, but long-
term clinical results are still unknown. Additional vaccines are under trials, such as MTB
subunit and DNA preparations [52].
In addition there is the problem in the variability of the host immunogenetic response, both to
BCG and to MTB [53]. Therefore various research projects are trying to identify, already
mentioned, polymorphisms in immune-associated and other genes, which may increase or
decrease the susceptibility to TB, such as the one which has been recently identified in a
Moroccan population [54] and another one in a Chinese ethnic group [55]. This subject lies
outside of the scope of this chapter, but it may lead to a better understanding of the processes
determining the fate of a MTB infection and assist in designing better vaccines, although they
may need to be population-targeted.
6. Summary
It has been attempted, in the present chapter, to describe in some detail the arms race between
MTB and its ancient human host, who uses the full scope of his sophisticated innate and adap‐
tive immune mechanisms to placate the enemy. The bacteria, which succeed to break the physi‐
cal barriers in the respiratory tract and reach the lung, are immediately surrounded by residing
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DCs and AMa, which recognize the bacterial PAMPs with their PRRs, such as surface TLRs.
This recognition triggers DC and macrophage activation, which results in the phagocytosis and
internalization of the bacteria in the phagolysosome, where they are submitted to toxic lysis.
Meanwhile the macrophages emigrate to the mediastinal lymph nodes, where the bacterial lip‐
id and peptide molecules are presented to CD4+ and CD8+ T cells via MHC-I and MHC-II, caus‐
ing T cell activation and clonal proliferation. The later return to the battlefield at the site of the
lung infection and try to complete bacterial elimination, by intensifying local inflammation. To
achieve that, the T cells and the macrophages secrete a series of cytokines, such as IFNγ, IL-12
and TNFα. Secreted chemokines attract more inflammatory cells, such as neutrophils.
Nevertheless, 90% of infected persons, who remain clinically asymptomatic, enter the stage of
latency, in which they continue to harbor dormant, albeit viable, bacteria in their macrophages
and 10% develop active clinical disease. This is due to numerous evasion tactics from the
immune system, that MTB has developed during its long cohabitation with the human host.
The bacterium may damage the phagosomal membrane and escape into the macrophage
cytosol, inducing necrotic cell death. It may interfere with the signaling to T cells via MHC
molecules, downregulate the secretion of IFNγ, promote the secretion of IL-10 and the activity
of CD4+Foxp3 T reg cells, thus dampening the protective inflammatory response. A hallmark
of the latency stage is granuloma formation, which is a complex structure, containing a core
of dormant bacteria in necrotic tissue, surrounded by neutrophils, macrophages, DCs and T
cells. This precarious balance may be easily disrupted, if, for whatever reason, immune
surveillance is weakened, causing bacterial breakthrough and clinical relapse.
So far, BCG is the only antituberculous vaccine widely available, which does confer a measure
of protection in children, but failed to arrest the spread of the infection in adult populations.
Many centers around the world are trying to identify immunodominant bacterial epitopes,
which could form the basis of a universal efficacious vaccine. So far, the 85A and 85B antigens,
in various constructs, seem to be presently the most promising, at least in animal models and
limited clinical trials. In addition, since the beginning of the 20th century, many mycobacterial
formulations and lately also cytokines, have been tried as specific immune stimulants. In most
cases they did induce generalized inflammation with significant side-effects, but with little
clinical benefit. However, recent technological developments, such as recombinant prepara‐
tions and DNA extracts, may obtain better results. To those have to be added numerous
projects trying to unravel the immunogenetic susceptibility or resistance factors.
One may estimate that within a decade, or so, better anti-tuberculous vaccines and treatments
will be developed, possibly targeted to specific populations.
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